| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | -0.0062 | 0.8 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | -0.008 | 0.8 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.8 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.0063 | 0.8 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | 0.0081 | 0.8 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.8 |
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | -0.035 | 0.8 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.0072 | 0.8 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.0097 | 0.8 |